Notably, the intravenous administration of a monoclonal antibody targeting the second extracellular loop of Cx43 reduces glioma growth and survival of experimental animals when used alone [88] or in combination with standard cancer therapy approaches [89]. The gene discussed is GJA1; the disease is glioma.